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  ABSTRACT 
 
Parkinson’s disease (PD) is the second most common age-related neurodegenerative 
disorder. Given its prevalence, researching PD is important to world health. The well-
known motor symptoms of PD are often accompanied by non-motor symptoms (NMS) 
including visuo-spatial learning and memory deficits. However, the mechanism whereby 
these NMS occur is unknown. PD is also characterized by the presence of protein 
aggregates termed Lewy Bodies (LBs). The mechanism whereby LBs form is unclear, 
although the fibrillization and aggregation of α-synuclein seem to be critical contributing 
factors.  
This thesis reports development of an animal model of PD to study NMS using 6-
Hydroxydopamine (6-OHDA) to produce partial bilateral lesions to the striata of mice. 
These lesions significantly reduced the tyrosine hydroxylase immunoreactivity in the 
striatum and hippocampus, mimicking the loss observed in PD patients. A deficit in 
visuo-spatial learning and memory in 6-OHDA treated mice was documented using the 
Barnes maze and Spatial Object Recognition test. Therefore, this model is expected to be 
useful for future study of the cause of these NMS.   
An analysis of mechanisms reported to underlie LB formation revealed the potential 
importance of the protease calpain and the peptidyl-prolyl isomerase PIN1 in α-synuclein 
fibrillization. Data from the literature demonstrated that calpain cleaves α-synuclein, 
promoting its aggregation, and PIN1 potentially regulates calpain activity. Preliminary 
data reveal that calpain-2 cleaves PIN1 in vitro. The relationship between calpain and 
PIN1 should be examined further in regards to PD. 
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INTRODUCTION 
Parkinson’s disease (PD) was first described as a neurological disorder by James 
Parkinson in his 1817 work “An Essay on the Shaking Palsy” (32). PD currently affects 
approximately 6 million elderly adults worldwide with a mean age of onset of 55 years 
old. It is the second most common neurodegenerative disease after Alzheimer’s (7) and 
currently affects 1.5% of the global population over 65 (55). The vast majority (95%) of 
PD cases are idiopathic, while only 5% are genetically based (62). 
 
The average lifespan is increasing with advances in modern healthcare. Therefore, higher 
prevalence and incidence of PD are expected to occur over time. Worldwide 
epidemiological studies give different estimates of PD, as it is difficult to compare rates 
of illness between countries. This discrepancy could be due to the variation in 
measurement method of prevalence and incidence or the difference in survival rates of 
various populations (58). Men have a higher chance of developing PD, with a relative 
ratio of 2.72:1 to women. Yet, the main factor known to promote sporadic PD is age (74). 
Wirdefeldt et al. performed a meta-analysis of the literature regarding potential 
environmental factors that could increase risk of PD. They find that there is mostly 
inadequate epidemiological data, with the exception of smoking tobacco or consumption 
of coffee reducing the risk of acquiring PD (86).  
 
The prevalence and potential growth of PD is staggering. While PD has been studied for 
almost 200 years, much more is unknown. By unraveling the mechanisms underlying the 
pathology, treatments would be aimed at the cause and not just the symptoms.  
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Lewy Body (LB) Formation is an Integral Mediator of PD Pathology 
PD is a neurodegenerative disease characterized by the progressive death of 
dopaminergic neurons originating in the substantia nigra pars compacta (SNpc) 
projecting to the dorsolateral putamen. This produces a striatal loss of dopamine, the 
hallmark of PD pathology (30). In addition to cell death, LBs are distinctive of the 
disease. These abnormal protein aggregates found in the cytoplasm of neurons are 
spherical of more than 15 µm in diameter, composed of a dense hyaline core. The core is 
granulovesicular in nature surrounded by a ring of radiating 8-10 nm fibrils. The central 
core appears differently than the rest of the inclusion when tissue is stained with 
haematoxylin and eosin. These morphological characteristics and specific staining allow 
for definitive identification of LBs as the primary diagnostic indicators of the disease (11, 
20, 22).  
 
Staining of PD patient’s brain tissue reveals the presence of LBs throughout the central 
and autonomic nervous system (22). LB formation and cell death are apparent in 
dopaminergic, noradrenergic, serotonergic, and cholinergic neurons in the SNpc, locus 
coeruleus, raphe, and nucleus basalis of Meynert/dorsal motor nucleus of vagas, 
respectively. LBs are also found in the cerebral cortex, specifically the cingulated and 
entorhinal cortices (20). Immunocytochemical staining and western blots of purified LBs 
reveal a predominance of the protein α-synuclein (6, 76). It is currently unknown as to 
what causes this protein to aggregate into LBs. By the time symptoms begin, LBs are 
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present in the SNpc and 60% of SNpc dopaminergic neurons have been lost with an 80% 
reduction in dopamine (11, 20). 
 
James Parkinson depicted PD as “involuntary tremulous motion…lessened muscular 
power…a propensity to bend the trunk forwards, and to pass from a walking to a running 
pace,” describing the three cardinal motor symptoms of tremor, akinesia, and rigidity 
(64). Motor symptoms are directly related to striatal dopaminergic loss and the 
corresponding disruption of the motor circuit (11, 42, 46, 67).  
 
Non-motor symptoms (NMS) also occur in up to 90% of PD patients and can often 
appear in the pre-motor stages of the disease (80). NMS include sleep disorders, olfactory 
dysfunction, neuropsychiatric issues of anxiety and depression, and cognitive 
impairment, to name a few (1, 15, 16, 49). Whereas the pathological mechanisms 
underlying PD motor symptoms are partially understood, the mechanisms of NMS are 
still largely unknown (29). LB formation in diverse brain regions could explain both 
motor and NMS. Indeed, the six-stage pathological system described by Braak et al. 
(based on the progression of LB development in diverse brain structures), would explain 
the appearance of NMS before motor symptoms, as the brainstem (theorized mediator of 
olfaction, depression, cognition, pain, constipation, and autonomic vagal control) stains 
for LBs before the SNpc is affected (11, 47).  
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Development of a 6-OHDA Mouse Model to Examine Visuo-spatial Learning and 
Memory Deficits  
Cognitive dysfunction, such as visuo-spatial deficits, can occur early in the disease and 
worsen as it progresses. PD patients perform poorly in tasks assessing the dysfunction of 
working memory that stores and processes visual and spatial information when compared 
to an age-matched healthy control and cognitively preserved group (46, 47). 
Understanding the underlying mechanisms of these symptoms could allow better 
treatment regiments to be developed for PD patients (53). 
 
As experiments determining the cause of these NMS in humans pose many ethical and 
technical issues, animals are often used to model the disease. PD is one of the many 
human diseases that do not spontaneously appear in animals, but the characteristic 
features of PD can be imitated. Mice, rats, and monkeys are commonly used to study the 
disease by injection of a neurotoxin, such as 6-Hydroxydopamine (6-OHDA) (8, 12, 17, 
20). 
 
6-OHDA must be injected into a brain structure due to its inability to cross the blood 
brain barrier (30). Once injected, terminals of catecholaminergic neurons selectively take 
up the toxin. 6-OHDA accumulates in the cytosol and generates reactive oxygen species 
(ROS) and quinones that attack nucleophilic groups, causing the loss of dopaminergic 
neurons (20). The 6-OHDA injection induces stable lesions within one to three weeks, 
with no further depletion of dopamine, nor a chance at recovery (12). This makes 6-
OHDA an excellent model for long-term behavioral analysis. The study of the NMS of 
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PD with 6-OHDA requires a partial bilateral injection of the toxin, causing a ~65% 
reduction of striatal dopamine, in order to avoid the confounding effect of motor 
imbalance on the cognitive performance and the possible compensation of one 
hemisphere (12, 54). This model has been used to examine cognitive impairment, 
depression, anxiety, pain, circadian deficits, and GI dysfunction (53). Based on the 
previous use of this toxin to study cognitive deficits, one aim of this work was to develop 
a functional 6-OHDA-mouse model of visuo-spatial learning and memory deficits for use 
in elucidating the underlying cause of these issues. 
 
α-Synuclein Aggregation Plays A Key Role in the Molecular Mechanisms 
Underlying Idiopathic and Genetic PD 
A prominent hypothesis as to the underlying cause of PD pathology suggests that α-
synuclein (Figure 1A) deposits into LBs causing SNpc dopaminergic death. α-Synuclein 
fibrillization via multiple mechanisms could contribute to aggregation.  
 
α-Synuclein has extraordinary conformational plasticity. The protein remains 
unstructured, forms monomeric species, or amyloid fibers depending on its environment 
(Figure 2). The protein passes through intermediates forms, including spheres of 2 to 6 
nm in diameter, chains of spheres (protofibrils), and circular protofibril rings in order to 
fibrillize. Its aggregation depends on nucleation, where a lag phase in polymerization is 
followed by exponential growth once aggregates have already formed (85).  
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The normal physiologic function for α-synuclein is only now being elucidated, and it has 
been suggested that it plays a role in the density of synaptic vesicles, plasticity, and 
modulating synaptic transmission (9). α-Synuclein is found in pre-synaptic terminal 
vesicles and portions of the nucleus interacting with lipid membranes. Davidson et al. 
showed through circular dichroism spectroscopy that binding with small (20-25 nm) 
vesicles composed of anionic phospholipids stabilized an α-helical secondary structure 
only in the N-terminal domain of α-synuclein. This promoted the formation of multimers, 
the precursors to fibril formation (5, 21). 
 
α-Synuclein Interacting with Synphilin-1 Promotes Aggregation 
α-Synuclein interacts with a variety of proteins (5, 85). Synphilin-1 (Figure 1B) was 
initially identified to interact with α-synuclein in a yeast two-hybrid screen, and the 
interaction was confirmed via NMR spectroscopy (87). Synphilin-1 gradually 
accumulates during development and immunohistochemical staining shows co-
localization with α-synuclein in pre-synaptic terminal vesicles (52, 87). Synphilin-1 has 
also been detected in the core of LBs through western blot and immunohistochemical 
analysis of PD patient samples (84). Interaction between the two proteins possibly occurs 
through the ankyrin-like repeats and the coiled-coil of synphilin-1 (52). 
 
An interaction at the ankyrin-like repeat has not been confirmed experimentally. 
However, when full-length synphilin-1 or its coiled-coil domain alone is over-expressed, 
the formation of α-synuclein aggregates is enhanced both in cell culture and mouse brain 
tissue. Xie et al. demonstrated through reciprocal fusion-protein fragment ‘pull downs’ 
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that the coiled domain of synphilin-1 and the first 12 residues of α-synuclein’s N-
terminus are necessary for the two proteins to interact. NMR spectroscopy suggests 
synphilin-1 exists in an antiparallel dimer attached by the two coiled-coil domains. α-
Synuclein binds to synphilin-1 at the coiled-coil domain opposite the side of 
dimerization. Once α-synuclein is bound, it becomes more compact and structured, 
promoting aggregation (as seen in NMR solution structures of the α-synuclein/synphilin-
1 complex). Indeed, synphilin-1 as a binding partner contributes to LB formation (87). 
 
Gene Mutations in SNCA and SNCAIP Causing Familial PD via Enhanced Aggregation 
Idiopathic and genetic PD may have a similar underlying pathology. Studying genetic PD 
is relevant to idiopathic cases with the assumption that the two forms share pathogenic 
mechanisms. α-Synuclein modifications enhancing its ability to form inclusions could 
play a vital role in both types of PD. This would allow the data from genetic models to be 
applied to all cases of the disease. Mutations in the gene encoding α-synuclein (SNCA) 
cause a familial form of the illness. Notably, each of the three missense mutations are 
located within the N-terminal lipid-membrane interacting amphipathic region of α-
synuclein, highlighting its importance in aggregation (57, 85).  
 
The gain-of-function A53T mutation provokes the formation of a beta-sheet stretch 
between amino acids 51 and 81 via loss of the induced α-helix between residues 51 and 
66. This effectively expands the hydrophobic region, increasing the formation of 
oligomeric species, the precursor to eventual aggregation (5, 57). The A30P mutation 
causes a disruption of the first induced α-helix in the structure, decreasing α-synuclein’s 
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affinity for anionic phospholipids by ~50%. This could cause enhanced deposition of the 
A30P α-synuclein variant, but has not yet been experimentally confirmed (5, 57, 85). The 
most recently discovered mutation E46K also alters α-synuclein’s interaction with 
phospholipids. This variant enhances aggregate formation by exposing hydrophobic 
surfaces within the structure, allowing for increased intermolecular interactions (i.e. 
hydrogen bonding) (5).    
 
Recently, a mutation in the synphilin-1 gene (SNCAIP) has also been identified to cause 
familial PD. It is unclear as to how mutation R621C causes changes in synphilin-1 
structure or function. Marx et al. found that expression of R621C synphilin-1 mutant 
increased inclusion formation in SH-SY5Y neurons. This further suggests that synphilin-
1 is an important mediator of LB formation (52).  
 
Oxidative Stress and Calcium Dysregulation as Potential Determinants of Idiopathic PD 
In an analysis of clinical data, Tanner et al. found a statistically significant correlation 
between the use of rotenone and the development of PD. The disease developed 2.5 times 
more frequently in those who were exposed to the pesticide (81). Rotenone acts as a 
mitochondrial complex I inhibitor, causing symptoms that mimic PD. Interestingly, this 
pesticide stimulates the formation of LBs in the brain (8). PD pathology has been 
attributed to mitochondrial complex I dysfunction. Parker and colleagues found a 
reduction of complex I activity in PD platelet mitochondria, while Schapira et al. found 
similar results in the SNpc of postmortem PD brain tissue through complex I activity 
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assays (25, 63, 72). This suggests that a mitochondrial deficit could play a role in 
idiopathic PD (20). 
 
Tanner and colleagues found the same correlation with another pesticide known as 
paraquat (81). The chemical acts as an oxidative stressor, mediating the formation of 
ROS, such as superoxide radicals, hydrogen peroxide, hydroxyl radicals, and 
peroxynitrite. Mitochondrial respiration produces ROS that is normally cleared by the 
body. In a diseased state, ROS are increased. Markers of oxidative stress appear in the 
SNpc of PD patients, such as tyrosine nitration, increased carbonyl levels, and 
methionine oxidation of α-synuclein (27, 39, 44, 48).  
 
Peroxynitrite production causes the formation of tyrosine-nitrated α-synuclein, found in 
LBs through the use of epitope-specific antibodies. In vitro co-incubation studies 
assessed by immunoelectron microscopy demonstrated that low concentrations of nitrated 
α-synuclein monomers increased unmodified α-synuclein’s propensity to aggregate. The 
nitration also caused a decrease in the rate of α-synuclein’s degradation by the 20S 
proteasome and calpain-1 seen via gel electrophoresis (39). The presence of carbonyl 
modifications is indicative of protein oxidation. Higher carbonyl content in proteins 
occurs during normal aging of the brain and corresponds to cognitive deficits in those 
areas. Floor et al. found higher carbonyl levels in soluble proteins from the SNpc of PD 
patients via dinitrophenylhydrazine assay and immunoblotting. This indicates an increase 
in ROS production accompanying PD (27, 44). It has been theorized that dopamine 
metabolism increases the formation of ROS. Leong and colleagues demonstrated that 
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incubating α-synuclein with dopamine caused the oxidation of the methionine residues in 
the α-synuclein detected via an increase in molecular weight corresponding to the 
expected change. The oxidation of these residues increased the protein’s propensity to 
aggregate, observed through higher molecular weight species apparent in gel 
electrophoresis (48). The data suggest an association between increased levels of 
oxidation and aggregate formation.  
 
Calcium uptake and storage are highly important to the function of mitochondria. When 
oxidative stress occurs, mitochondrial membranes become disrupted, reducing the 
efficiency of calcium reuptake. This leads to higher intracellular calcium in the 
susceptible neurons. As SNpc dopaminergic neurons have low intrinsic calcium 
buffering, these cells are particularly vulnerable to altered cellular calcium concentrations 
(25, 26, 44).  
 
Dysregulation of the Calpain/Calpastatin System Promotes α-Synuclein Aggregation 
Higher levels of free intracellular calcium have been proposed to increase the activity of 
calpain, a non-lysosomal, calcium-dependent cysteine protease found in all mammalian 
cells (Figure 3A, B) (78, 89). Esteves and colleagues demonstrated through fluorometric 
calpain assays and calpain-specific breakdown products that there is an increase in 
calcium-dependent calpain activation associated with dysfunctional mitochondria in a 
cellular model of PD (25). 
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Cleaved forms of α-synuclein are often found in LBs. Calpain has been shown to cleave 
α-synuclein at several locations as shown by using epitope-specific antibodies in a 
western blot analysis. Cleavage may occur in the N-terminal region between amino acids 
9 and 10 and between 57 and 58, and at the C-terminus between residues 122 and 123. 
Higher calpain activity due to dysregulated calcium from mitochondria may increase 
cleavage of α-synuclein and subsequent LB formation, as argued by Esteves (25). This is 
supported by the immunohistochemical detection of calpain in the halo surrounding LBs  
(23, 38, 56). 
 
Bioinformatic analysis of clinical data by Allen and colleagues suggests that two single 
nucleotide polymorphisms (SNPs) in the gene of calpastatin (CAST), the endogenous 
inhibitor of calpain (Figure 3C), may predispose Caucasian individuals with European 
ancestry to idiopathic PD (2, 3, 20). A potential decrease in calpastatin function due to an 
SNP, and corresponding increase in calpain activity, could allow for increased cleavage 
and aggregation of α-synuclein.  
 
Can PIN1 Promote Aggregation of α-Synuclein Through Potential Regulation of 
Calpastatin and Synphilin-1?  
The mechanism whereby the calpain/calpastatin system is regulated is currently 
unknown. Recently, the peptidyl-prolyl cis/trans isomerase PIN1 (Figure 1C) has been 
suggested to regulate calpastatin’s ability to inhibit calpain through either binding or 
isomerization. PIN1 may promote aggregation by increasing the formation of cleaved α-
synuclein species because of a reduction in calpastatin efficacy. This concept was 
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proposed using crude cell lysate pull downs, demonstrating interaction between PIN1 and 
calpastatin (51). However, this result has yet to be confirmed with purified proteins.   
 
Immunohistochemical staining documented that PIN1 was present in 50-60% of LBs. In 
examining PIN1’s role in α-synuclein aggregation, it was found that PIN1 does not act 
directly on α-synuclein, but on synphilin-1. Co-immunoprecipitation showed that PIN1 
interacts with synphilin-1 directly at phosphorylated sites at S211 and S215 promoting 
interaction between the α-synuclein and synphilin-1. This was demonstrated by an 
increase in aggregation when α-synuclein is co-transfected with PIN1 into N27 
dopaminergic cells (69). PIN1 could play a significant role in the development of LBs 
through multiple mechanisms. 
 
PIN1’s Potential Regulation of the Calpain/Calpastatin System in PD is Pertinent to 
Examine Further 
Calpain and PIN1 have both been implicated in α-synuclein aggregation via different 
mechanisms. PIN1 interaction with calpastatin would increase calpain’s cleavage of α-
synuclein by reducing the efficiency of calpastatin, leading to increased LB development. 
The calpain system and PIN1 appear to be prominent in the molecular mechanisms 
underlying α-synuclein fibrillization and LB formation. Based on a literature review and 
preliminary data, this topic should be examined further in regards to its role PD 
pathology. 
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MATERIALS AND METHODS 
Animals 
Male and female C57BL/6J mice, 10 weeks old, weighing 25-30 g, were purchased from 
Taconic (Tornbjerg, Denmark). The animals were housed in groups of no more than five 
mice per cage and maintained in a 12 hour light-dark cycle at a stable temperature of 
22°C, with food and water ad libitum. All experiments were carried out during the light 
phase and in accordance with the guidelines of the Research Ethics Committee of 
Karolinska Institutet and the Swedish Animal Welfare Agency, as well as the guidelines 
for the use of animals in biomedical research provided by the European Communities 
Council Directive 86/609/EEC. 
 
6-OHDA Lesioning 
Mice were anesthetized with a mixture of Hypnorm (BETAPHARMA), Midazolam 
(PANPHARMA 5 mg/ml) and water (1:1:2) injected intra peritoneal (i.p.) in a volume of 
10 ml/kg, then mounted in a stereotactic frame (David Kopf Instruments, Tujunga, CA) 
with a mouse adaptor. The skull of the mouse was exposed and a researcher drilled one 
burr hole per side. Each mouse received a bilateral injection into the dorsal striatum as 
previously described (71) of 19 mM 6-Hydroxydopamine Hydrochloride (6-OHDA-HCl) 
(1 uL freshly dissolved in a vehicle 0.9% saline and 0.02% ascorbic acid)  (Sigma-
Aldrich, Sweden AB). The injections were made according to the following coordinates 
(mm) (65): anterior-posterior (AP): +0.6, medio-lateral (L): +/-2.2 and dorsal-ventral (V): 
-3.2. The injections were made by a metallic injector connected by a plastic tube to a 5 µl 
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Hamilton syringe mounted on a pump. After each injection, the injector was left in place 
for 3 minutes to allow complete diffusion of the drug. The control animals (sham) were 
subjected to the same procedure with the vehicle lacking 6-OHDA (1 µl). Before every 
new surgery all the equipment (injector, tube, and syringe) was cleaned with ethanol and 
water. After the injections, the skull was covered and the skin was disinfected and 
stitched with metallic clips. The mice were hydrated with a solution of 15% glucose 
injected i.p. in a volume of 10 ml/kg and placed under red light until they gained 
consciousness. After the surgery the animals were observed daily and fed with milk as 
considered necessary. Carprofen (250 µl dissolved in 0.9% saline at a concentration of 5 
mg/kg) (Sigma-Aldrich, Sweden AB), an analgesic drug, was injected subcutaneously for 
three days following surgery and every 24 hours after as needed.  
The mice were given a recovery period of three weeks before behavioral evaluations. 
 
Statistical Analysis 
Data were analyzed using one- or two-way ANOVA, and post hoc comparisons between 
groups were made using Fisher’s post hoc analysis and t-tests with equal variances for 
groups of 2, when relevant. A p value of less than 0.05 was considered significant. * p < 
0.05,  ** p < 0.01 and *** p < 0.0001.  
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Behavioral Evaluations 
Barnes Maze 
The table consisted of a white circular open arena (125 cm in diameter) elevated to 89 cm 
by four metal legs. There were 36 circular holes around the edge of the table (4.5 cm in 
diameter) equally spaced (5.5 cm inter-hole distance) and placed 1.3 cm from the edge of 
the table (Fig 5A). The dark grey opaque plastic escape box (20.6 x 6.3 x 10.4 x 4.1 cm) 
was mounted in brackets under one of the holes. White opaque curtains surrounded the 
room to block extraneous cues. Extra-maze cues were a triangle (69.4 cm on each side) 
with 6 alternating white and black stripes (5.2 cm in width), a black circle (64.2 cm in 
diameter), and a square (65 cm on each side) with 5 white boxes (18.7 cm on each side) 
on a black surface, forming a checkered pattern (Fig 5B). The cues were placed on the 
walls of the room centered at 1.4 m high. Three round Honeywell Oscillating Table fans 
were placed 16.1 cm away and level to the table equidistant from each other and allowed 
to rotate on medium speed. The position of the fans was unchanged for the entirety of the 
experiment. Bright lights located on the ceiling illuminated the apparatus. The mouse was 
placed in a dark grey opaque plastic tube (12.3 cm tall, 11 cm in diameter), which was 
removed manually at the start of each session. A video camera above the field was 
connected to a video recorder and a monitor, recording the movement of the mouse. 
One mouse at a time was tested. To reduce intra-maze odor cues, each mouse was 
assigned a different hole for both habituation and training but maintained the same hole 
during the entire session.  
The entire apparatus was cleaned with 70% ethanol between each mouse.  
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Mice received one habituation trial in which they were placed beside their respective 
escape hole (with the box underneath the hole) in a transparent glass cylinder for 4 
minutes, and gently guided into the box for 1 minute. This procedure allowed the mice to 
experience the aversive bright lights and practice descending into the escape box. During 
the habituation trial, extra-maze cues were placed behind the curtain to prevent learning 
the escape hole’s location. 
The acquisition phase consisted of 7-9 training days with two trials per day. For each 
trial, a mouse was placed into the start tube located in the center of the maze, the start 
tube was raised, and the trial ended when the mouse entered the escape box. After each 
trial, the mice remained in the escape box for 30 seconds before being returned to the 
holding cage located in a dark room adjacent to the test room for the inter-trial interval 
(10–15 minutes). For each session, mice were given 5 minutes to locate the escape hole, 
after which they were guided to the escape hole and coaxed to enter. Mice that still failed 
to enter the escape hole were placed directly into the escape box. If a mouse climbed 
back onto the maze after entering the escape box, the mouse was guided back until it re-
entered the escape box. A mouse that fell into an incorrect hole was returned to its 
holding cage, and the trial was re-run after all the other mice had completed the 
respective training trial.  
Learning was measured by latency, the time required for the mouse to locate, not enter, 
the escape hole (37, 61). An experimenter blind to the groups manually scored the 
latency.  
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Spatial Object Recognition (SOR) Test 
The apparatus was a square field (55 cm on each side) with walls (50.2 cm high) made of 
dark gray plastic material. A visually uniform environment surrounded the open field. A 
dim light located on the ceiling illuminated the apparatus. A video camera above the field 
was connected to a video recorder and a monitor, recording the movement of the mouse. 
Five objects were simultaneously present in the field: (1) a red block (3.1 cm on all sides, 
1.9 cm high); (2) a blue top (3.2 cm diameter, 1.3 cm high); (3) a yellow battery (4.2 cm 
long, 1 cm diameter); (4) an orange figurine (2 cm diameter, 3.5 cm high); and (5) a 
snowman figurine (2 cm diameter, 4.5 cm high). The initial arrangement was square with 
object 5 in the center (Fig 6A, S1-S3). The configuration was changed for the test by 
moving two objects: object 5 was placed below the previous location of object 1, which 
was itself displaced to the periphery of the apparatus so that the initial square 
arrangement was altered to form a polygon-shaped arrangement (Fig 6A, S4). 
Mice were individually subjected to three successive 6-minute sessions, separated by a 3-
minute delay (S1-S3), during which the subjects were returned to their home cages. On 
the next day (24 hours later), mice were subjected to only one 6 minute session (S4), with 
the objects displaced relative to the original arrangement as described.  
Object exploration was evaluated by the time the animal spent in contact with an object. 
A contact was defined as the snout of the mouse touching an object. The duration of 
contact was expressed as mean per object. Response to spatial change was assessed by 
comparing the mean time in contact with the objects belonging to each category 
(displaced (DO) and non-displaced (NDO)) in S4 minus the mean time spent in contact 
with the same object category in S3 (DO S4-S3; NDO S4-S3) (68). 
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Molecular Assays for Mouse Studies 
Western Blotting 
Ten of the mice used in the Barnes maze were sacrificed via guillotine. The striatum and 
hippocampus were bilaterally dissected. The striata and hippocampi were sonicated in 
750 µl and 500 µl of 1% SDS in water, respectively, and boiled for ten minutes. 
Aliquots (5 µl) from sonicated striata or hippocampi were used for protein quantification 
with the bicinchoninic acid (BCA) assay kit (Pierce, Rockford, IL). Equal amounts of 
protein (5 µg) from each sample were loaded onto 10% Tris Glycine polyacrylamide gels 
(37.5:1 pore size). Proteins were separated by SDS-PAGE and transferred overnight to 
polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Little Chalfont, UK) (1). 
The protein of interest was detected with mouse anti-TH antibody (1:3000, Millipore, 
Billerica, MA), and the PVDF membranes were incubated in horseradish peroxidase 
(HRP)-conjugated secondary goat anti-mouse antibody (1:30000, Millipore, Billerica, 
MA). The protein signal was visualized by enhanced chemiluminescence (ECL) (Pierce, 
Rockford, IL) and quantified using Quantity One software (Bio-Rad). 
 
Immunohistochemistry 
Mice were anaesthetized with pentobarbital (100 mg/kg, i.p., Sanofi-Aventis, France) and 
perfused transcardially with 4% (w/v) paraformaldehyde in 0.1 M sodium phosphate 
buffer pH 7.5. After overnight post-fixation in the same solution, brains were cut with a 
vibratome (Leica, Nussloch, Germany) in 40 µm slices from hippocampus (anterior-
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posterior (AP) between -1.94 and -2.06 mm, from bregma (intersection of the coronal and 
sagittal sutures on the vertex of the skull)) and striatum (AP -0.26 mm, from bregma). 
 
TH in the Striatum  
Slices were incubated in permeabilizing solution (0.3% Triton X-100, 1% bovine serum 
albumin (BSA), 5% normal goat serum in Phosphate-buffered saline (PBS)) for 60 
minutes. After washing in PBS, sections were incubated overnight at 4°C with anti-TH 
mouse monoclonal antibody (1:300; Millipore, Stockholm, Sweden), rinsed again and 
incubated for 1 hour with goat Cy3-coupled anti-mouse secondary antibody (1:400; 
Jackson Laboratory, Bar Harbor, ME). Sections were then mounted in 2.5% 1,4-
diazabicyclo [2.2.2] octane (DABCO) (Sigma-Aldrich, Sweden). After processing, 
images of the striatum were taken at 5x magnification using sequential laser scanning 
confocal microscopy (Zeiss LSM 510, Jena, Germany).  
 
Arc or pERK in the Hippocampus  
Slices were incubated in permeabilizing solution (0.3% Triton X-100, 1% BSA in Tris-
buffered saline (TBS)) for 45 to 60 minutes. After washing in TBS, sections were 
incubated overnight at 4°C with anti-Arc mouse monoclonal antibody (1:200; Santa Cruz 
Biotechnology, Santa Cruz, CA) or anti-pERK rabbit monoclonal antibody (1:200; Cell 
Signaling Technology, Beverly, MA), rinsed again and incubated for 1 hour with goat 
Cy2-coupled anti-mouse secondary antibody or goat Cy3-coupled anti-rabbit secondary 
antibody (1:400; Jackson Laboratory, Bar Harbor, ME). Sections were then mounted in 
2.5% DABCO (Sigma-Aldrich, Sweden). After processing, images of the hippocampus 
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were taken at 10x magnification using sequential laser scanning confocal microscopy 
(Zeiss LSM 510, Jena, Germany). 
 
Molecular Assays for Calpastatin-PIN1 Studies 
Purification of calpain, calpastatin, and PIN1 
BL21(DE3) Escherichia coli were previously transformed with two plasmids encoding 
recombinant six-Histidine tagged wild type (WT) rat calpain-2 (capn2-H6) in a pET24a 
vector and the requisite small subunit capns-1 in a pACpET vector. Other BL21(DE3) 
Escherichia coli were previously transformed with a pET24a plasmid encoding 
recombinant six-Histidine tagged double phosphomimic (PM2) calpastatin domain 1 
(D1) or with a pMCSG7 plasmid encoding recombinant six-Histidine tagged human 
PIN1 (Addgene plasmid 40773 from Dustin Maly). All cells were induced to express 
recombinant protein with 0.5-0.6 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) for 
14-18 hours at room temperature. Cells were harvested by centrifugation at 4000 xg for 
15 minutes at 4oC. The pellets were washed with 0.15 M NaCl and recentrifuged under 
the same conditions prior to storing at -80oC.  
For protein purification, calpain and calpastatin expressing cells were re-suspended in 
lysis buffer (50 mM 3-(N-morpholino) propanesulfonic acid (MOPS) pH 7.5 and 10 mM 
β-mercaptoethanol (β-ME)). For extraction of cells expressing calpain, the buffer also 
had 10 mM ethylene glycol tetraacetic acid (EGTA), 10 mM ethylene diamine tetraacetic 
acid (EDTA), and 0.2 mM phenylmethanesulfonylfluoride (PMSF)/benzamidine. The 
cells were lysed by sonication on ice (Branson Sonicator 450). Cells expressing 
calpastatin were subjected to three freeze (-80oC) thaw cycles in lysis buffer and the 
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supernatant from the final thaw was diluted with 50 mM MOPS pH 7.5, 5 mM EGTA, 5 
mM EDTA, and 5 mM β-ME. PIN1 cells were re-suspended in 25 mM MOPS pH 8.0, 10 
mM imidazole, 0.10 M NaCl, 0.4 mM EGTA, 0.2 mM EDTA, and 0.1 mM β-ME. All 
suspended cells or cell lysates were centrifuged at 30000 xg for 20 minutes at 4oC, and 
the supernatant with the protein of interest present was isolated (see below). Total protein 
was measured by Bradford assay. Concentration of calpastatin was also measured by 
A280 using an extinction coefficient of 4675 M−1cm−1 (19).  
Ion exchange and dye affinity chromatography: Supernatant with calpain or calpastatin 
was loaded onto a DEAE Sephacel ion-exchange chromatography column pre-
equilibrated with buffer A (50 mM MOPS pH 7.5, 5 mM EGTA, 5 mM EDTA, and 5 
mM β-ME). For calpain, a wash with 0.15 M NaCl in buffer A removed weakly bound 
proteins from the resin. Elution by 0.5 M NaCl in buffer A yielded the protein of interest. 
The calpastatin peak was pooled and dialyzed against 25 mM MOPS pH 8.0, 10 mM 
imidazole, and 0.10 M NaCl. The calpain peak was pooled and loaded onto a pre-
equilibrated Reactive Red Agarose affinity column. The bound proteins were eluted using 
distilled deionized water into final concentrations of 25 mM MOPS pH 8.0, 10 mM 
imidazole, 0.10 M NaCl, 0.4 mM EGTA, 0.2 mM EDTA, and 0.1 mM β-ME.  
Nickel affinity chromatography: The pooled calpain peak, calpastatin eluted from DEAE, 
or PIN1 supernatant was loaded onto a pre-equilibrated Ni-NTA agarose affinity column 
(Qiagen). Bound proteins were eluted by increasing the imidazole in the buffer to 100 
mM (calpastatin) or 250 mM (calpain and PIN1). Pooled calpain was dialyzed against 50 
mM MOPS pH 7.5, 2 mM EGTA, 2 mM EDTA, 0.5 mM dithiothreitol (DTT) and 
0.025% sodium azide. Pooled calpastatin was dialyzed against 25 mM MOPS pH 7.5. 
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Pooled PIN1 was dialyzed against PIN1 storage buffer (20 mM MOPS pH 7.5, 0.5 mM 
DTT, and 0.1 M NaCl). Calpain and PIN1 aliquots were frozen with liquid nitrogen and 
stored at -80oC. Calpastatin aliquots were frozen and stored at -20oC. 
 
SDS Polyacrylamide Gel Electrophoresis 
Protein purity and digestions were analyzed by electrophoresis on an 8%, 10%, or 12% 
Tris Tricine polyacrylamide gels (32:1 pore size) with samples that had been boiled for 
two minutes in SDS-PAGE sample buffer (0.0625 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 6.8, 10% glycerol, 5% β-ME, 2.5% SDS). 
Protein was visualized using 0.1% Coomassie blue and 0.05% amido black in 40% 
methanol and 10 % acetic acid. Gels were imaged using the Chemimager 4400 Low 
Light Imaging System (Alpha Innotech Corporation) and saved as digital tiff files. 
Images represent original stained gels. PageRuler was used as protein molecular weight 
(MW) markers (Thermo Scientific, Waltham, MA). MW was analyzed by graphing the 
logarithm of the MW markers versus the measured Rf values. The resulting graph was 
used to estimate MW of the bands. 
 
Fluorescein isothiocyanate (FITC)-casein Hydrolysis to Assay Calpain and Calpastatin 
Assays were composed of 73 µM FITC-casein, 50 mM MOPS pH 7.5, 0.15 M NaCl, 10 
mM CaCl2, and 1 mM DTT. Varying concentrations of WT or PM2 calpastatin D1 
diluted in 25 mM MOPS pH 7.5 or PIN1 diluted in PIN1 storage buffer were added as 
indicated. Incubation for 20 minutes at 25oC began when WT recombinant calpain-2 
diluted in 50 mM MOPS pH 7.5, 2 mM EGTA, 2 mM EDTA, 0.025% sodium azide, and 
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1 mM DTT (MEEND) was added to the samples in a final concentration of 104 nM. 
Incubation stopped when cold trichloroacetic acid (TCA) was added for a final 
concentration of 3.5% and assays were allowed to precipitate overnight at 4oC. Samples 
were centrifuged at 16000 xg for 10 minutes at room temperature. The supernatant was 
collected and diluted by 0.5 M Tris pH 8.5. Assays were analyzed using a Perkin-Elmer 
LS50 B luminescence spectrophotometer (excitation at 488 nm and emission at 518 nm). 
Slit widths varied between assays (2.5-4.0 nm) but were consistent between samples in an 
experiment. Controls with or without enzyme were in triplicate; experimental samples 
were performed in duplicate. 
 
Digestion of PIN1 by Calpain-2 
PIN1 was incubated with calpain in a molar ratio of 1:100 of calpain to PIN1 for 0, 5, 15, 
30, or 45 minutes at 25oC in final concentrations of 50 mM MOPS pH 7.5, 10 mM CaCl2, 
and 1 mM DTT. Controls were incubated at 0 and 45 minutes in the absence of calpain. 
Samples were quenched by the addition of SDS sample buffer with 5 mM EGTA and 
subjected to gel electrophoresis (see above) with a final concentration of 3 µg PIN1.  
 
Western Blotting 
SDS samples from PIN1 digestion by calpain-2 (0 and 45 minutes of both control and 
experimental) were loaded onto a 10% Tris Tricine polyacrylamide gel (32:1 pore size) 
and subjected to SDS-PAGE gel electrophoresis. Final concentrations of PIN1 loaded 
ranged from 0.5 to 2 µg as indicated. Proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane (Millipore, Billerica, MA) and blocked overnight in 3% 
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gelatin in 1% TBS. The protein of interest was detected with mouse anti-PentaHistidine 
HRP-conjugated antibody (1:1000, Qiagen). The protein signal was visualized by Clarity 
Western ECL kit (Bio-Rad).  
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RESULTS 
Partial 6-OHDA lesion reduces dopaminergic innervation to the striatum and 
hippocampus.  
Male and female mice were given a bilateral 6-OHDA lesion in the dorsal striatum. 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthesis of dopamine, 
as it catalyzes the formation of L-DOPA. The loss of TH is representative of the death of 
the dopaminergic neurons. Therefore, PD is a TH-deficient syndrome as well a 
dopamine-deficient syndrome (35). To confirm the lesion’s efficacy, TH levels were 
assessed in the striatum and hippocampus of sham and lesioned mice. The western blot 
analysis shows a 70% decrease in the amount of TH in the striatum in lesioned mice 
compared to sham (Figure 4A). There is a corresponding 70% decrease of TH in the 
hippocampus (Figure 4B).  
Immunohistochemistry was performed to visually verify the loss of TH in the striatum. 
The results show a visible, substantial decrease in the TH due to the lesion compared to 
sham, confirming the western blot results (Figure 4C). This is indicative of a successful 
partial lesion. Indeed, the model mimics the depletion of dopamine expected of PD NMS. 
 
The Barnes Maze assesses visuo-spatial learning and memory in mice. 
Once the lesion was confirmed, behavioral evaluations were used to assess if the mice 
possessed a visuo-spatial memory and learning deficit. The Barnes maze was determined 
to be potentially useful at evaluating the desired cognitive issues in the mice. To use the 
Barnes maze, it was necessary to develop a working protocol with the available apparatus 
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(Figure 5A). Over seven days, wild-type mice significantly increased their average speed 
in finding the goal hole by ~100 seconds (Figure 5C). Therefore, the protocol is effective 
at determining the function of visuo-spatial learning and memory in mice. This 
verification allows the continued use of the protocol for 6-OHDA lesioned mice.  
 
The Spatial Object Recognition (SOR) test assesses spatial learning and memory in 
mice. 
The SOR test was used to analyze another aspect of the mice visuo-spatial memory 
deficit. Wild-type mice were tested to determine the efficacy of the protocol for the SOR 
test. The ratio of exploration time for the displaced objects (DO) is high, at four seconds 
more exploration after the change. There is a slight reduction of one second in the non-
displaced objects (NDO) exploration time, concomitant with the increase of DO 
exploration (Figure 6B). This demonstrates that the animal discriminated and 
remembered the spatial modification, confirming the working protocol, allowing for its 
use in further experimentation.  
 
Parkinsonian mice possess a visuo-spatial memory deficit.  
Once the protocols had been verified, the behavioral evaluations were available for use 
with lesioned mice. Visuo-spatial learning and memory in sham and lesioned mice were 
assessed with both the Barnes maze and the SOR test. 
The mice learned the location of the hole over nine days of training on the Barnes maze, 
where both groups reduced overall time to find the hole by ~110 seconds. However, the 
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lesioned mice were eventually able to find the hole in 40 seconds compared to the sham 
mice finding the hole in only 10 seconds (Figure 7A). This demonstrates that the lesioned 
mice were unable to learn and remember the location of the goal hole relative to visual 
extra-maze cues as well as the sham mice.  
The sham mice had a similar result to the wild-type mice in the SOR test with a 2 second 
increase in DO exploration and 0.2 second decrease in time examining NDO, 
demonstrating the expected spatial learning. The lesioned mice have a reduction in both 
DO and NDO exploration time of 1 to 1.5 seconds, with no significant difference 
between the two (Figure 7B). Therefore, the lesioned mice did not recognize and respond 
to the spatial change of the objects. 
The model effectively mimics the visuo-spatial memory and learning deficits seen in PD 
patients. This allows the model’s use in examining the underlying mechanisms. 
 
Arc and pERK are not definitively associated with the memory deficits seen in the 6-
OHDA lesioned mice. 
Visuo-spatial memory is believed to be located in the hippocampus. Activity-regulated 
cytoskeleton-associated protein (Arc), an immediate early gene, is found in many 
cognitive disorders. It is possible to measure and correlate the changes in expression of 
Arc to the effect of the disease on hippocampal function in animal models (75). Another 
functional marker to investigate the occurrence of plastic processes is phosphorylated 
extracellular signal-regulated kinase (pERK). ERK is an essential component of the ERK 
signal transduction mechanisms underlying behavioral memory formation (79).  
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To see if the lesion caused a reduction in synaptic plasticity, immunohistochemistry of 
the hippocampus was performed to assess the levels of Arc and pERK. The mice were 
sacrificed one hour post-stimulation with the Barnes maze.  
Approximately one cell is visibly stained positive for Arc in both sham and lesioned 
samples (Figure 4D). This is not a definitive determination of the correlation between Arc 
and the effect of the lesion on visuo-spatial memory.  
There are eight cells visibly stained for pERK in lesion and sham mice (Figure 4D). The 
low number of cells prevents analysis of the results. This gives a lack of clarity on the 
association between pERK and the memory changes due to the lesion.  
While there are visuo-spatial deficits present in this model, further analysis needs to 
occur to determine the underlying pathology. 
 
Phosphomimic (PM2) and wild-type (WT) calpastatin domain 1 (D1) possess a similar 
ability to inhibit calpain-2 in vitro 
In order to examine PIN1’s potential regulation of calpastatin, it was necessary to create 
the proper conditions for PIN1 to act on the protein. PIN1 is a unique PPIase in that it is 
selective for phosphorylated serine (S) or threonine (T) residues followed by a proline (P) 
residue. Parallel FITC-casein assays were performed with calpastatin (D1) and its double 
phosphomimic (PM2), where S/T residues potentially targeted by PIN1 had been 
previously changed to E residues through site-directed mutagenesis (Figure 3D). Assays 
were performed to determine that PM2 retained the ability to inhibit calpain-2 activity. 
Calpain was inhibited equally by both WT and PM2 at concentrations of 20 nM, 40 nM, 
and 60 nM (15%, 25%, and 35% respectively). PM2 displayed more effective inhibition 
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at 80 nM (80% inhibition) and 100 nM (85% inhibition) when compared to WT (45% 
inhibition at 80 nM and 55% inhibition at 100 nM) (Figure 8). This indicates the ability 
to use PM2 calpastatin D1 in future assays examining calpastatin’s inhibition of calpain. 
 
Recombinant PIN1 is cleaved by calpain-2 at the N-terminus in vitro 
In order to determine if calpain-2 cleaves PIN1, the two enzymes were incubated under 
conditions that favored calpain-2 activity. The recombinant PIN1 is cleaved by calpain-2, 
seen by the loss of the control band at ~21 kDa (black arrow) and appearance of two new 
bands of a major product at ~18 kDa (blue arrow) and a minor product ~13 kDa (red 
arrow) (lanes 3-7) (Figure 9).  
For an estimate of the location of cleavage on PIN1 by calpain-2, a western blot was 
performed using anti-PentaHistidine HRP conjugate antibody due to the presence of a 
six-Histidine tag on the N-terminal end of PIN1. The western blot demonstrates that PIN1 
is cleaved at the N-terminus as seen by the loss of signal (lanes 7 and 8) and lack of a 
lower molecular weight band formation corresponding to the major or minor product 
(Figure 10). 
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DISCUSSION 
A bilateral 6-OHDA lesion of the midbrain dopaminergic system produced a partial 
depletion of dopamine that mimics a relatively early stage of PD. The loss of dopamine is 
evidenced by a distinct reduction in TH immunoreactivity in the striatum and the 
hippocampus. The mice demonstrate decreased visuo-spatial learning and memory due to 
the lesion. These results did not find a definitive correlation between the lesion and Arc 
or pERK in the hippocampus. Overall, the 6-OHDA mice effectively model the visuo-
spatial memory and learning deficit in PD. 
 
This mouse model of PD reproduces an initial stage of the disease, as suggested by the 
partial (~70%) reduction of TH immunoreactivity observed in the striatum. This protocol 
has been well established to reproduce the parallel degeneration of dopaminergic and 
noradrenergic neurons described in PD patients (11, 40, 42). This type of lesion allows 
the mice to develop NMS with a lack of overt motor symptoms (24, 35). The decrease in 
TH immunoreactivity produced by 6-OHDA affects not only the striatum, but also the 
hippocampus. Bonito-Oliva and colleagues found an 85% reduction of hippocampal TH 
in this model, which was abolished with the pre-treatment of desipramine, a 
noradrenergic reuptake inhibitor (10). This suggests a reduction of TH in the 
hippocampus is due to the lesion’s effect on not only dopaminergic, but on noradrenergic 
neurons that account for a high amount of TH positive cells in the hippocampus (7). The 
reduction observed in the present results only showed a ~70% decrease in hippocampal 
TH, possibly due to variability in the mice tissue composition and the lesion’s efficacy.  
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For the purposes of this study, the Barnes maze is preferred to measure visuo-spatial 
memory deficits. While the partial bilateral injection of the toxin did not cause overt 
motor symptoms, it may cause fine motor impairments that affect results in a wet maze, 
such as the Morris water maze. Therefore, a dry maze affords greater accuracy (59). Fox 
and colleagues measured visuo-spatial memory in a mouse model of traumatic brain 
injury by replacing the Morris water maze with the Barnes maze. The stress and physical 
demands on the mice due to the wet maze affected the results and made the behavioral 
deficit appear more prominent. Their results suggest that because of the trauma to the 
experimental mice, the Barnes maze was more effective at accurately measuring visuo-
spatial memory (28). This promotes the use of the Barnes maze when the mice have 
impairments that can affect performance in a water maze, such as the 6-OHDA lesion.  
 
It was necessary to determine a working protocol for the Barnes maze apparatus 
available. As apparatus design could influence results, a reproducible protocol was vital. 
O’Leary and colleagues found that a large table (122 cm) was more effective at 
accurately measuring visuo-spatial memory in rats due to the reliable use of extra-maze 
visual cues and strategy for spatial search. The apparatus used for this study had a 
diameter of 125 cm, giving credence to its efficacy (61). The protocol was effective at 
measuring the ability of the mice to learn the location of the goal hole using the extra-
maze cues (60).  
 
The SOR test is an effective measure of the mouse’s response to a spatial change. This is 
paralleled in the literature as a useful tool to measure response to spatial modifications in 
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mice. Roullet et al. reliably demonstrated that glutamate receptors play a role in 
processing spatial information using the SOR test to measure changes in mice treated 
with NMDA antagonists (68). If the mice have functional spatial memory, there is an 
increase in exploration of the DO in the test phase and corresponding loss of time 
exploring the NDO. The controls in the study by Roullet et al. mirror this work, further 
validating the present protocol (68). The SOR test could be used in further experiments 
due to the expected DO and NDO ratios. 
 
The Barnes maze evaluation demonstrated that the lesioned mice did not reach the 
efficiency of the sham mice in finding the goal hole. The ~70% loss of dopaminergic 
neurons impaired the level of learning but not the ability to learn. Branchi et al. found 
that there were no deficits in 6-OHDA mice in the Morris water maze with a bilateral 
lesion of 45%. A ~ 75% loss is required for spatial deficits to be apparent, in line with the 
current results. Given that the Barnes maze is an associative task, the lesioned mice have 
a deficit in their ability to create a spatial construct based on visual cues. Mura et al. 
found similar deficits in visual spatial memory from subjecting rats with a bilateral 6-
OHDA lesion to the Morris water maze, despite the drawbacks of a wet maze. Their 
findings are similar to the current results, where the experimental mice learned the task, 
but were unable to execute as well as the sham mice (59).  
 
The SOR test demonstrated that the sham mice could react appropriately to the spatial 
change. They spent more time exploring the DO than the NDO. In contrast, the lesioned 
mice have the same exploration for both DO and NDO, showing their lack of response to 
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a spatial modification after 24 hours. The SOR is a non-associative task, and the data 
demonstrates a reduction in the animal’s ability to form spatial constructs without visual 
cues. Roullet and colleagues study revealed that an impairment of the mice after 
administration of the NMDA antagonist is similar to the results obtained with 6-OHDA 
lesioned mice (68). Leonibus and colleagues illustrated that the SOR test measures 
changes in PD mice that were treated with glutamate receptor blockades. Therefore, the 
SOR is a useful tool in PD research (49). In the present results, it seems that the sham 
mice had a reduced and more variable response to the spatial change than the wild-type 
mice used to validate the protocol. This could be due to effects of the surgery performed.  
 
Spatial deficits are known to appear in this model (49, 59). The bilateral 6-OHDA 
injection allows other cognitive deficits to be studied. Bonito-Oliva et al. have 
demonstrated that a loss of synaptic plasticity in the hippocampus due to the same lesion 
in mice corresponds to decreased long-term recognition memory observed through the 
reduction of ERK signaling (10). It stands to reason that other such deficits would be 
apparent in the partial bilateral 6-OHDA model.  
 
In the present results, only one cell in both sham and lesion samples stained for Arc is 
visible. This does not allow a clear determination as to whether or not the lesion caused a 
change in plasticity. The antibody’s efficacy at staining the samples was confirmed under 
identical conditions with tissue known to contain Arc (data not shown), confirming the 
antibodies function. Multiple cells are visible in the samples of the hippocampus stained 
for pERK, but the quantity is not sufficient for an accurate comparison between sham and 
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lesion samples. This result is not definitive, as there has been evidence of pERK and Arc 
involvement in the reduction of memory associated with PD (10, 73). It is possible that 
one-hour post stimulation is the incorrect timing of sacrifice to observe Arc or pERK, as 
thirty minutes post spatial learning stimulation is used reliably in protocols for observing 
the expression of both plasticity markers in rats (34). It is also conceivable that the 
stimulation was insufficient for Arc or pERK to be expressed. While it is known that the 
ERK signaling pathway is crucial to long-term recognition memory in the hippocampus, 
other pathways that were not examined may mediate visuo-spatial memory (10).  
 
Partial dopamine depletion leads to an impairment of visuo-spatial learning and memory 
in a 6-OHDA mouse model of PD. This is a functional representation of NMS in humans, 
as it has been shown that patients suffer from similar impairments. PD patients did not 
perform as well as the age and education-matched controls in conditions requiring 
remembering locations in space. They also showed increased errors regarding working 
memory in forming a spatial construct (66). Braak staging suggests that LB formation 
stimulates the reduction in cognitive function. However, the 6-OHDA model does not 
create classic LBs, suggesting that neuronal degeneration plays a more prominent role in 
the deficits presently observed (47). This model is limited given that LB formation in 
various brain regions could contribute to the deficits in humans (43). 
 
PD research is far off from finding a cause, let alone a cure. Further work should be done 
to determine the underlying mechanism behind this impairment. An assessment of the 
link between synaptic plasticity markers and the behavioral effects due to the lesion 
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should be done with the verified model. It is necessary to continue further 
experimentation with altered procedures to determine if Arc or pERK are affected by the 
lesion and give the requisite behavioral deficits in visuo-spatial memory. To assess if the 
ERK plasticity pathway is involved, it would be possible to treat mice with an ERK 
inhibitor or promoter to see if the deficit is worsened or improved, respectively. It is also 
necessary to examine different markers or pathways involved in synaptic plasticity. These 
could include the mTOR pathway, calcium/calmodulin-dependent protein kinase II 
(CaMKII), brain-derived neurotrophic factor (BDNF) or calcineurin (18, 79, 90). It could 
be possible to investigate the mTOR pathway’s involvement with an mTOR inhibitor. 
This could be followed by an attempt to ameliorate the effect with medication such as L-
DOPA.  
 
Data demonstrate that lower concentrations of PM2 and WT calpastatin D1 have a 
similar ability to inhibit calpain-2, diverging at higher amounts in vitro. Calpain-2 
appears to cleave PIN1 at the N-terminus in vitro.  
 
There was very little measurable difference in inhibition of calpain by calpastatin WT or 
PM2. Because phosphorylation in the cell is transient and the kinase that phosphorylates 
calpastatin is unknown, a phosphomimic increases the experimental feasibility. It has 
been previously shown that PIN1 can act on a phosphomimic (50).  S/T residues were 
replaced with E residues, more favored by PIN1 than D residues. This was confirmed 
experimentally through similar enzymatic efficiency in coupled PIN1 activity assays 
when WT or phosphomimic substrates were utilized (50, 88). While the higher 
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concentrations of the two forms of calpastatin diverge in the ability to inhibit calpain, the 
similarity at lower concentrations allows for the use of PM2 in inhibition assays of 
calpain where calpastatin concentration is lower to see an effect of added variables.  
 
It is unclear if PIN1 regulates calpastatin. This concept was first proposed using crude 
cell lysate pull downs. GST-PIN1 pulled calpastatin out of a cell lysate and the potential 
interaction was supported by calpastatin co-immunoprecipitating with an anti-PIN1 
antibody (51). However, purified protein assays may prove more difficult. There could be 
multiple reasons why a direct experiment would not provide a clear result. If calpain is 
inhibited extensively by too much calpastatin, it is difficult to see any change in activity. 
In contrast, PIN1 requires large amounts of substrate because only 3-10% of the substrate 
is naturally in a cis conformation (50). It is reportedly unfavorable for proteins to remain 
in the cis conformation as it must be stabilized by surrounding folded structure, which is 
not possible with intrinsically unstructured proteins such as calpastatin. In order to 
observe an effect of PIN1, the substrate must be trapped in a trans conformation by 
selective proteolysis or a coupled assay. The calpastatin-calpain complex is tightly bound 
(19) and PIN1 may be unable to disrupt it. Further, the assays were performed under 
conditions favoring calpain, not PIN1, activity. It seems likely that calpastatin is acted on 
by PIN1, given its proclivity for unstructured protein substrates (50). Even in perfect in 
vitro conditions, PIN1 may not regulate calpastatin directly.  
 
Another reason why PIN1 might not have any effect on calpastatin is potential cleavage 
by calpain. Data show that calpain cleaves recombinant PIN1 in vitro. PIN1 as a substrate 
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is relatively surprising, as calpain often prefers large proteins to cleave. There are two 
bands in the gel of potential significance. The band at ~18 kDa is the major product 
formed in the degradation of PIN1. The human PIN1 construct has a histidine tag 
followed by a tobacco etch virus protease cleavage site. It is possible that the ~18 kDa 
band represents PIN1 after calpain-2 has cleaved off both tags leaving the PIN1 protein 
intact, corresponding to the molecular weight change predicted by ExPasy. This cleavage 
would not be physiologically relevant. The minor product ~13 kDa band is intriguing. If 
calpain cleaves PIN1 between the WW and PPIase domain, there would be the 
production of a ~13 kDa protein fragment, similar to the size of the remaining catalytic 
domain (as measured by ExPasy). While the specific location of cleavage is still 
unknown, western blot data demonstrate that the N-terminus is cleaved, as neither the 
~18 or ~13 kDa band appears on the membrane, further suggesting the removal of the 
affinity tags. Prediction of cleavage sites by the calpain.org database did not correspond 
to the observed truncation of PIN1. As calpain cleavage sites are highly variable, this 
result could be due to the difficulty in accurate predictions. 
 
The method by which PIN1 binds and isomerizes its substrates is unclear (41). In some 
cases, the WW domain is necessary for the PPIase domain to function (as seen through 
western blot analysis of characterized substrates with only the PPIase portion present) 
(41). Therefore, cleavage between the two domains could effectively attenuate PIN1 
activity, although this has not been confirmed experimentally. Liu argued that 
calpastatin’s ability to inhibit calpain is reduced in the presence of PIN1. This would 
likely cause a concomitant increase in calpain activity. If calpain were to then cleave 
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PIN1, potentially removing it’s catalytic activity, a novel feedback regulation mechanism 
appears wherein calpain regulates itself.  
 
Grant and colleagues demonstrated that calpain is actively cleaving spectrin (measured 
by calpain-specific spectrin breakdown products) for at least 2 weeks post 6-OHDA 
lesion in the SNpc and striatum of a rat model (33). In a SH-SY5Y cell model of PD 
stimulated with MPP+ and rotenone, a rise of calcium concentration (measured via 
increased emission after addition of ratiometric dye Fura-2AM) activated calpain in the 
dopaminergic cells as measured by calpain-specific spectrin breakdown and 
immunohistochemical staining with an antibody against active µ-calpain. Inhibition of 
calpain activity can be neuroprotective in PD. When calpain was inhibited with SNJ-
1945, damaging pathways such as oxidative stress (measured by caspase 10, Cox-2, and 
p10) and proteolysis of spectrin (examined by changes in calpain specific breakdown 
product) were attenuated (45). In a rat model of MPP+ and rotenone, mitochondrial 
dysfunction also promoted an increase in intracellular calcium (measured by an increase 
in emission after adding ratiometric dye Fura-2AM), inducing an increase in calpain-
specific spectrin breakdown products. Calpeptin (a calpain inhibitor) significantly 
blocked apoptosis occurrence, conferring cytoprotection (examined through a reduction 
in DNA ladder formation) (70). A rat 6-OHDA model of PD given L-DOPA therapy had 
up to ~60% reduced severity and amplitude of L-DOPA induced dyskinesia when calpain 
was inhibited by MDL28170 or roscovitine (measured by the percentage of asymmetry in 
the stepping and cylinder test) (13). While spectrin breakdown is not a very accurate 
measure of calpain activity, these findings combined suggest that calpain plays a role in 
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the neurodegeneration due to PD, and may play a much larger role in PD development 
and response to therapy than previously believed.  
 
Figure 11 is a compilation of potential molecular mechanisms underlying LB formation 
from the literature and preliminary data. SNPs can play a role in PD pathogenesis. This is 
evidenced by the SNP in the gene encoding NADH dehydrogenase 3 decreasing 
susceptibility of PD in those with Caucasian ancestry (57). In contrast, two separate 
bioinformatics studies analyzing available clinical data compellingly suggest that SNPs in 
CAST play a role in the pre-disposition to develop idiopathic PD, although unconfirmed 
experimentally (2, 3). Liu et al proposed that PIN1 reduces calpastatin’s ability to inhibit 
calpain either through binding or isomerization, but a crude lysate pull down is not 
definitive.  
 
Mitochondrial dysfunction leading to oxidative stress causes α-synuclein to fibrillize 
through nitration and carbonyl formation (62). Oxidatively modified α-synuclein is more 
likely to aggregate than unaltered α-synuclein (20). Other diseases, such as Huntington’s 
disease (HD), may have a similar mechanism. However, unlike PD where complex I is 
affected, HD develops reduced activity in complex II, III, and IV. This also increases the 
oxidative stress, suggesting a role for ROS in neurodegenerative disease (14). 
Mitochondrial dysfunction causes calcium dysregulation (seen by an increase in emission 
from the staining with Indo-1/AM dye) in PD, increasing the activation of calpain (seen 
through increased cleavage of a fluorigenic substrate) to cleave α-synuclein (25). This 
also occurs pathogenically in HD, where calcium signaling is affected in the 
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mitochondria, leading to increased calpain cleavage of the N-terminal end of the 
huntingtin protein (83). 
 
Calpain cleaves α-synuclein in a variety of locations, which could have significance for 
aggregation (23, 38). α-Synuclein C-terminus is a negative regulator of the protein’s 
aggregation. When the C-terminus is cleaved by calpain between residues 122 and 123, 
there is a propensity of the protein to aggregate faster. It also acts as a nucleation site for 
more inclusions to form (observed through sedimentation analysis) (9, 23). It has also 
been shown through high-pressure liquid chromatography that calpain cleaves α-
synuclein after amino acid 57 within the amphipathic region of the protein. This portion 
of α-synuclein is crucial to fibrillization (seen via ion-mobility mass spectroscopy), and 
the fragment is therefore less likely to aggregate (82). When calpain cleaves α-synuclein 
between residues 9 and 10 aggregation may be attenuated, but this has not been 
confirmed experimentally. The loss in aggregation may also be due to a loss in α-
synuclein/synphilin-1 binding, as the 12 N-terminal residues of α-synuclein are necessary 
for this interaction. The change in aggregation due to cleavage by calpain at either end of 
α-synuclein suggests both a neuroprotective and neurodegenerative role of calpain in PD 
(38, 85). 
 
PIN1 contributes to aggregation of the α-synuclein into LBs (31). This occurs through 
the binding of synphilin-1 at phosphorylated residues (illustrated by reciprocal co- 
immunoprecipitation of wild-type and non-phosphorylatable (control) forms of synphilin-
1) (69). PIN1 increases the propensity of synphilin-1 to bind and aggregate with α-
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synuclein’s N-terminal end (4). PIN1 is up regulated in human PD midbrain as well as in 
cell culture and animal models of PD. It has also been found in LBs by 
immunohistochemical staining. PIN1 increases α-synuclein aggregation in the N27 
dopaminergic cell line induced with MPP+ (seen through immunohistochemistry). When 
cells are pre-treated with a PIN1 inhibitor, the aggregates do not form. This suggests that 
PIN1 is necessary for inclusion formation (31, 69). Synphilin-1 may increase α-
synuclein’s aggregation through stabilization, increasing half-life and insolubility. 
Synphilin-1 inhibits the degradation of wild-type α-synuclein by the 20S proteasome, 
examined through a reduction in cleavage products compared to control at identical time 
points in gel electrophoresis (4, 31). Marx and colleagues recently discovered a mutation 
of R621C in synphilin-1 that may have caused PD in two un-related patients. However, 
given that the mutation is located in a region that has an unknown function separate of 
it’s binding with α-synuclein, this mutation could cause PD by another, unknown 
mechanism (52). 
 
Further work is needed to confirm if PIN1 affects calpastatin. It would be necessary to 
promote the cis conformation of calpastatin through selective proteolysis of the trans 
conformer of calpastatin or in the presence of lithium trifluroethanol, which promotes 
stabilization of the cis conformer. PIN1 activity also needs to be confirmed 
experimentally so that calpastatin could be pre-incubated with PIN1 under conditions in 
which it is active. This would allow a high amount of calpastatin present with PIN1, and 
dilution to a much lower concentration of calpastatin to inhibit calpain. At the same time, 
it would prevent calpain’s cleavage of PIN1 having an effect on the PIN1-calpastatin 
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interaction. A confirmation of the cleavage site would be necessary by Edmann 
degradation of the major cleavage product. If calpastatin still does not appear to have an 
effect, it would be prudent to examine if PIN1 and calpastatin bind directly. Indirect 
binding would require in vivo studies. The first step would be determination of PIN1 and 
calpastatin’s localization in the cell. Once localization has been confirmed, an induced 
increase in calcium may reveal clues as to the signaling pathways involved in the 
calpastatin-PIN1 interaction. To confirm PIN1 and calpastatin’s role in PD, knockdown 
or over-expression of either protein in a model may lead to novel insights.  
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FIGURES 
 
 
Figure 1: Protein map of α-synuclein, synphilin-1, and PIN1. (A) α-Synuclein: an unstructured, heat stable, 
charged protein of 140 amino acids. The N-terminal region of the protein contains an amphipathic region 
and a hydrophobic non-amyloid component (NAC) domain with six highly conserved repeats (KTKEGV), 
characteristic of all of the synuclein family members. It is followed by an acidic C terminus. Arrows 
indicate amino acid missense mutations causing familial PD. Adapted from Moore et al. 2005 (57). (B) 
Synphilin-1: a 919 amino acid protein with ankyrin-like repeats in its N-terminal portion, a coiled-coil 
domain, an ATP/GTP binding site, and a C-terminus containing a conserved region between 612-689 of 
unknown function. Insert shows an interspecies comparison of the amino acid region containing the 
missense mutation associated with familial PD. Adapted from Marx et al. (52) (C) PIN1: an 163 amino acid 
protein containing an N-terminal WW binding domain and a C-terminal catalytic peptidyl-prolyl isomerase 
(PPIase) domain. Adapted from Stanya et al. (77). 
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Figure 2: α-Synuclein Fibrillogenesis. Intrinsically unstructured monomers of α-synuclein are induced to 
oligomerize into protofibrils (spheres, chains, or rings) rich in β-pleated sheets. The structures fibrillize into 
amyloid-like filaments that deposit into Lewy bodies. Figure adapted from Moore et al. (57). 
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Figure 3: Calpain-2 structure with map and calpastatin map with sequence comparison. (A) Ribbon 
structure of calpain-2. Progression of the rainbow indicates N to C terminus. Sourced from PDB 1DF0. (B) 
Domain map of calpain-2: composed of a large subunit (~80 kDa), made up of domains 1 through 4, and a 
small subunit (~28 kDa), comprised of domains 5 and 6. Domains 4 and 6 contain penta-EF hand domains 
that bind to calcium. Calpain undergoes a conformational change after calcium binding, forming the active 
site cleft for substrate cleavage in domains 1 and 2. (C) Domain map of calpastatin: the 673 amino acid 
intrinsically unstructured protein contains a leader domain followed by four identical inhibitory domains. 
Each domain is able to inhibit one calpain and is composed of three subunits A, B, and C. Calpastatin 
subdomains A and C attach to the penta-EF hands, while the B domain blocks the active cleft of calpain in 
the presence of calcium (19, 36). (D) Calpastatin domain 1 amino acid sequence comparison between wild 
type (top line) and double phosphomimic (bottom line). Mutations of T135E and S243E bold and 
underlined. Subdomains bracketed in red.  
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Figure 4: Partial 6-OHDA lesion reduces dopaminergic innervation to the striatum and hippocampus and 
has no definitive connection to changes in Arc and pERK. (A) Quantification of TH immunoreactivity in 
the striata of sham-lesioned (sham) mice and 6- OHDA-lesioned (lesioned) mice. Data is calculated as 
percent of sham and shown as means ± SEM (n = 10 per group). Student t-test indicates a significant group 
effect (p < 0.0001). *** p < 0.0001 vs sham. (B) Quantification of TH immunoreactivity in the hippocampi 
of sham and lesioned mice. Data is calculated as percent of sham and shown as means ± SEM (n = 10 per 
group). Student t-test indicates a significant group effect (p < 0.0001). *** p < 0.0001 vs sham group. (C) 
Immunofluorescence images depicting TH-positive cells in the striata of sham and lesioned mice. (D) 
Immunofluorescence images depicting Arc and pERK-positive cells in the hippocampi of sham and 
lesioned mice. 
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Figure 5: Visuo-spatial memory can be assessed using the Barnes maze. (A) Image of the Barnes maze 
apparatus used. (B) Visual extra-maze cues used for spatial association with the location of the goal hole. 
(C) Latency of wild-type mice to find the goal hole in the Barnes maze over seven days. Data are calculated 
as time (in seconds) to find the hole, and are shown as means ± SEM (n = 14). Repeated measure (days of 
training) one-way ANOVA indicates a main effect of the time [F(1,13) = 6.637, p < 0.0001]. 
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Figure 6: Visuo-spatial memory can be assessed using the Spatial Object Recognition (SOR) test. (A) 
Arrangement of objects in training sessions 1-3 (S1-S3) and test session 4 (S4). (B) SOR test performed 
with wild-type mice 24 hrs after familiarization. Data indicate the time (in seconds) spent exploring the 
displaced object (DO) or non-displaced object (NDO) and are calculated as a ratio of the test session (S4) 
minus the last training session (S3) e.g. DO S4-S3; NDO S4-S3. Bars represent means ± SEM (n = 8). 
Student t-test indicates a significant group x object exploration (p < 0.012). ** p < 0.01 vs displaced object 
same group.  
	  60 
 
Figure 7: Visuo-spatial memory is reduced in lesioned mice versus sham mice. (A) Latency of sham- 
(sham) and 6-OHDA-lesioned (lesioned) mice to find the goal hole in the Barnes maze over nine days. 
Data are calculated as latency (in seconds) to find the hole, and are shown as means ± SEM (sham n = 8, 
lesioned n = 7). Two-way ANOVA with repeated measures (days of training) of time versus the group 
shows a significant interaction [F(8,8) = 3.808, p < 0.05]. One-way ANOVA shows that both groups learned 
the position of the hole [sham: F(1,7) = 9.088, p < 0.0001 and lesioned: F(1,6) = 5.066, p < 0.001]. (B) SOR 
test performed in sham and lesioned mice 24 hrs after familiarization. Data indicate the time spent (in 
seconds) exploring the displaced object (DO) or non-displaced object (NDO) and are calculated as a ratio 
of the test session (S4) minus the last training session (S3) e.g. DO S4-S3; NDO S4-S3. Bars represent 
means ± SEM (sham n = 8, lesioned n = 7). Two-way ANOVA indicates a significant effect of the lesioned 
(p < 0.0007) and between DO and NDO (p < 0.02). One-way ANOVA indicates a significant effect 
between DO and NDO within the sham group (p < 0.02), no significant interaction between NDO and DO 
in the lesioned group. There is no significant interaction between the sham and lesioned group (p < 0.07). * 
p < 0.05 vs displaced object same group, Fisher post-hoc test. 
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Figure 8: Phosphomimic (PM2) and wild-type (WT) calpastatin domain 1 (D1) possess a similar ability to 
inhibit calpain-2 in vitro. Inhibition of calpain-2 by PM2 calpastatin D1 (blue line) and WT calpastatin D1 
(red line). Concentrations of calpastatin ranges from 0 to 100 nM, as shown. Data (n=1) calculated as 
percentage of calpain-2 activity after subtraction of the background from the average of duplicates at each 
concentration. Controls performed in triplicate.  
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Figure 9: Recombinant PIN1 is cleaved by calpain-2 in vitro. SDS-PAGE analysis of recombinant PIN1 
digest by calpain-2 stained with Coomassie blue and amido black. Full-length recombinant PIN1 appears at 
21 kDa (black arrow) incubated with calpain-2 for 0, 5, 15, 30, and 45 minutes (lanes 3, 4, 5, 6, and 7, 
respectively). PIN1 incubated without calpain-2 as a positive control for 0 and 45 minutes (lanes 1 and 9, 
respectively). Experiment performed with Nabeel Hashmi.  
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Figure 10: Recombinant PIN1 is cleaved by calpain-2 at the N-terminus in vitro. Western blot analysis of 
PIN1 digestion by calpain-2 using an anti-PentaHistidine horseradish peroxidase (HRP) conjugated 
antibody. Full-length recombinant PIN1 appears at 21 kDa. All samples loaded in duplicate at low (0.5 µg: 
odd lanes) and high (2 µg: even lanes) concentrations. Positive control (PIN1 incubated without calpain-2) 
at 0 minutes (lanes 1, 2) and 45 minutes (lanes 9, 10). Negative control (untagged casein) in lanes 5, 6. 
PIN1 digested by calpain-2 at 0 minutes (lanes 3, 4) and 45 minutes (lanes 7, 8). 
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Figure 11. Schematic of Potential Molecular Mechanism Underlying α-Synuclein Aggregation in PD. SNPs 
in the gene of calpastatin disrupt its ability to inhibit calpain. PIN1 isomerizes/binds to calpastatin, 
preventing its inhibition of calpain. Disrupted calcium signaling from the mitochondrial dysfunction 
activates calpain. Calpain cleaves α-synuclein at the C-terminus. Cleaved alpha-synuclein binds to 
synphilin-1 or forms fibrils. Oxidative stress from dysfunctional mitochondria produces reactive oxygen 
species (ROS), causing fibrillization of α-synuclein. Fibrils or complexes form aggregates. CAST = gene 
of calpastatin, α-SYN = α-synuclein, SPH-1 = synphilin-1.  
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